News
AMRX
19.71
+1.97%
0.38
Amneal Pharmaceuticals (AMRX) Gains FDA Nod As Fair Value Sits Higher
Simply Wall St · 5h ago
Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform
NASDAQ · 20h ago
Amneal Pharmaceuticals Price Target Announced at $27.00/Share by Oppenheimer
Dow Jones · 1d ago
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27
Benzinga · 1d ago
Amneal: Even My Bull Case Barely Justifies $20/Share
Seeking Alpha · 2d ago
Biotech Stocks At 52-Week Highs - AMRX, BLSM, NEOG. NEO
NASDAQ · 2d ago
Amneal Pharmaceuticals Up Over 11%, on Track for Highest Close Since October 2018 -- Data Talk
Dow Jones · 3d ago
Why Is Amneal (AMRX) Stock Rocketing Higher Today
Barchart · 3d ago
Chris Schott Initiates Buy on Amneal, Citing Lanreotide Launch and Biosimilar-Driven Growth Outlook Through 2027
TipRanks · 3d ago
Weekly Report: what happened at AMRX last week (0914-0918)?
Weekly Report · 3d ago
Ipsen Shares Fall After Early Launch of U.S. Generic Rival
Dow Jones · 3d ago
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Amneal Pharmaceuticals (AMRX)
TipRanks · 3d ago
How Investors May Respond To Amneal Pharmaceuticals (AMRX) FDA Approval Launch
Simply Wall St · 5d ago
Amneal Pharma Gains FDA Approval For Lanreotide Injection
NASDAQ · 5d ago
Stocks to Watch: Paramount Skydance, Warner Bros. Discovery, Accenture, Amneal Pharmaceuticals
Dow Jones · 5d ago
Amneal Gains FDA Approval For Generic Lanreotide Injection; Launches Drug Immediately
NASDAQ · 5d ago
Amneal Gets FDA Approval for Generic Hormone Drug
Dow Jones · 6d ago
Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide
TipRanks · 6d ago
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Barchart · 6d ago
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Seeking Alpha · 09/17 18:21
More
Webull provides a variety of real-time AMRX stock news. You can receive the latest news about Amneal Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.